ReviewTherapeutic advances in medical oncology2025

Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.

Kazumasa Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.